Lyra Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Impairment of property and equipment
Impairment of right-of-use assets
Restructuring and other related charges
Total operating expenses
Loss from operations
Other income:
Interest income
Other Income
Total other income
Loss before income tax expense
Income tax expense
Net loss
Other comprehensive loss:
Unrealized holding income (loss) on short-term investments, net of tax
Comprehensive loss
Net loss per share attributable to common stockholders—basic and diluted
Weighted-average common shares outstanding—basic and diluted
Net loss per share attributable to common stockholders- basic
Net loss per share attributable to common stockholders-diluted
Weighted-average common shares outstanding-basic
Weighted-average common shares outstanding-diluted

Comments